Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 3Terminated 2Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Leukemia, Myeloid, Acute 1Carcinoma 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × OTHER × ficlatuzumab × Clear all
NCT02109627 2020-03-24

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

University of California, San Francisco

Phase 1 Terminated
17 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02277184 2017-11-13

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

University of Pittsburgh

Phase 1 Terminated
1 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡